BARDA DRIVe EZ-BAA (EZBAA - 22-100-SOL-00003)
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The BARDA - ASPR / DAAPPO / BARDA DCMA (under Health And Human Services) has issued the BARDA DRIVe EZ-BAA (EZBAA - 22-100-SOL-00003), seeking research and development (R&D) proposals for Nebulization Therapy to Prevent and Treat Pulmonary Foam Caused by Inhaled Chemical Agents. The primary goal is to generate data to support an initial FDA meeting and advance the Technical Readiness Level (TRL) through TRL 5. This opportunity was published on April 27, 2026.
Scope of Work
This R&D effort includes:
- Early-stage formulation and analytical development of the drug product.
- Nebulizer characterization, including flow rates and particle size distribution.
- Bioanalytical development to support non-GLP studies (e.g., PK, dose range finding, chlorine exposure proof-of-concept).
- Development of an overall regulatory strategy.
- Advancing the technical readiness level through TRL 5 to meet future contract vehicle requirements.
Contract & Timeline
- Type: Proposed R&D Contract under an EZ-BAA
- Set-Aside: None specified
- Published: April 27, 2026
- Response Due: Not specified (typical for EZ-BAAs, which may have rolling submissions or specific deadlines not provided in this metadata)
Evaluation
Proposals will be evaluated based on their scientific merit and alignment with BARDA's objectives for advancing nebulization therapy.
Additional Notes
For inquiries, contact the BARDA DCMA DRIVe Team at DRIVeAcquisitions@hhs.gov or Richard Hall at Richard.Hall@hhs.gov.